New York, May 25, 2026, 11:13 EDT
Harvard Bioscience Inc. traded at $5.59 heading into the holiday-shortened week, gaining 1.3% Friday and sitting around 6.5% higher than the close last Friday. U.S. markets will be shut Monday for Memorial Day. Nasdaq is showing May 25 as a market holiday in 2026.
Tuesday could be another test for HBIO. Shares got a lift last week, but the May 12 drop still looms. The stock fell 20.9% that day after earnings and finished at $5.41, historical data shows.
Harvard Bioscience says it wants investors to focus on better margins, new products, and its manufacturing changes, even as demand from academics and distributors remains weak. Gross margin rose to 59% in the first quarter, up from 56% a year ago. Revenue slipped to $20.8 million from $21.8 million. Net loss was $3.4 million. The company kept its full-year revenue growth target at 2% to 4%. CEO John Duke called first-quarter sales “in line with our expectations” and said the company’s consolidation in manufacturing is “on track.” GlobeNewswire
Adjusted EBITDA came in at $0.8 million. CFO Mark Frost said on the earnings call that the Mesh MEA, SoHo and BTX lines make up “about 15%-20% of our revenue right now,” offering investors a sense of what the new products contribute. Investing
Harvard Bioscience has just one event listed for the week ahead. The company said Duke and Frost will participate in the Benchmark Healthcare House Call Virtual Conference, hosted by StoneX, on Thursday, May 28. This follows their appearance at Sidoti’s micro-cap virtual event on May 21.
Harvard Bioscience isn’t in an easy fight. In its annual report, the company said it faces much larger competitors, naming Agilent, Revvity and Thermo Fisher Scientific. Most rivals have more products, bigger sales forces and deeper pockets. HBIO doesn’t try to match them everywhere—instead, it’s banking on growth from its niche lines in organoids, electroporation and preclinical telemetry.
The market wasn’t much of a tailwind. The iShares Russell 2000 ETF, which follows small-caps, climbed Friday. But the SPDR S&P Biotech ETF slipped. HBIO shares moved more on company news than any sector push.
Harvard Bioscience’s setup looks shaky. The company’s quarterly filing blamed the revenue drop on weaker sales to academic research groups in the Americas and to Asian Pacific distributors. Interest expense jumped to $1.7 million from $0.9 million. The same filing put the effective interest rate on borrowings at 17.3%, tightening the margin for error if second-half sales or Project Viking savings disappoint.
Stock structure is also a factor here. The $5.59 quote is after the reverse split. Harvard Bioscience said its 1-for-10 reverse stock split took effect March 13, with shares trading on the new basis starting March 16. A reverse split means fewer shares but a higher share price, without changing the company’s value.
